These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9670114)

  • 1. Muscle rigidity induced by fluphenazine in rats is antagonized by L-DOPA, an antiparkinsonian drug.
    Ossowska K; Konieczny J; Lorenc-Koci E; Schulze G; Coper H; Wolfarth S
    J Physiol Pharmacol; 1998 Jun; 49(2):311-7. PubMed ID: 9670114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats.
    Wardas J
    Pol J Pharmacol; 2003; 55(2):155-64. PubMed ID: 12926542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
    Wardas J; Konieczny J; Lorenc-Koci E
    Synapse; 2001 Aug; 41(2):160-71. PubMed ID: 11400182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
    Ossowska K; Konieczny J; Wolfarth S; Pilc A
    Neuropharmacology; 2005 Sep; 49(4):447-55. PubMed ID: 15919101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-oleoyl-dopamine decreases muscle rigidity induced by reserpine in rats.
    Konieczny J; Przegalinski E; Pokorski M
    Int J Immunopathol Pharmacol; 2009; 22(1):21-8. PubMed ID: 19309549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portable device for quantifying parkinsonian wrist rigidity.
    Caligiuri MP
    Mov Disord; 1994 Jan; 9(1):57-63. PubMed ID: 7908119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats.
    Konieczny J; Ossowska K; Schulze G; Coper H; Wolfarth S
    Psychopharmacology (Berl); 1999 Apr; 143(3):235-43. PubMed ID: 10353425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomechanical and electromyogram characterization of neuroleptic-induced rigidity in the rat.
    Wu YN; Hyland BI; Chen JJ
    Neuroscience; 2007 Jun; 147(1):183-96. PubMed ID: 17507166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
    Lorenc-Koci E; Wolfarth S
    Eur J Pharmacol; 1999 Nov; 385(1):39-46. PubMed ID: 10594343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of a case of neuroleptic malignant syndrome with bromocriptine.
    Zubenko G; Pope HG
    Am J Psychiatry; 1983 Dec; 140(12):1619-20. PubMed ID: 6650696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Alam M; Mayerhofer A; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
    Konieczny J; Ossowska K; Wolfarth S; Pilc A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct; 358(4):500-2. PubMed ID: 9826074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

  • 19. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats.
    Singh A; Naidu PS; Kulkarni SK
    Indian J Exp Biol; 2003 Nov; 41(11):1264-8. PubMed ID: 15332494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
    Lorenc-Koci E; Wardas J; Wolfarth S; Pilc A
    Brain Res; 2001 Jun; 903(1-2):177-84. PubMed ID: 11382401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.